RBC Capital Maintains Outperform on Avid Bioservices, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge maintains an Outperform rating on Avid Bioservices (NASDAQ:CDMO) and raises the price target from $7 to $8.
April 30, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Sean Dodge maintains an Outperform rating on Avid Bioservices and raises the price target from $7 to $8.
The upgrade in price target by a reputable analyst like Sean Dodge from RBC Capital is a strong positive signal for Avid Bioservices. It suggests confidence in the company's future performance and growth potential, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100